Gilead Sciences, Inc. (NASDAQ:GILD) Scaling the Fight Against Cancer

0
697

Kite, a Gilead subsidiary Company (NASDAQ:GILD), and Sangamo Therapeutics (NASDAQ:SGMO) Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer

Gilead Company is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Kite being a subsidiary of Gilead is engaged in the development of innovative cancer immunotherapies.

In its quest to keep being a world pharmaceutical leader, the company has continued to build partnerships and have collaborations of all kinds with partners in sciences, academia, businesses and local communities.

Through partnerships the company has been able to develop innovative medicines and deliver to people in the most effective and efficient mannerisms.

The companies have entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.

Kite announced that it aims to use Sangamo’s ZFN technology to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers.

Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients.

The emergence of gene editing as a tool to edit immune cells holds promise in the development of therapies with potentially improved safety, efficacy and efficiency to accelerate our efforts to develop next-generation autologous cell therapies, as well as allogeneic treatments.

Besides entering partnerships with other stakeholders, Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced today that they have entered into a definitive agreement to acquire Cell Design Labs, gaining new technology platforms that will enhance research and development efforts in cellular therapy.

There have also been recent changes in the company’s top management with the aim of creating a more streamlined approach in handling the company’s operations.

James Meyers, Executive Vice President, Commercial Operations, will retire. Mr. Meyers joined Gilead in 1996 as a regional sales director and was appointed to his current role in 2016, he however was retained in the company in an advisory capacity to consult on priority projects.

LEAVE A REPLY

Please enter your comment!
Please enter your name here